HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The LKB1-AMPK pathway-friend or foe in cancer?

Abstract
Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.
AuthorsD Grahame Hardie
JournalCancer cell (Cancer Cell) Vol. 23 Issue 2 Pg. 131-2 (Feb 11 2013) ISSN: 1878-3686 [Electronic] United States
PMID23410967 (Publication Type: Comment, Journal Article)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: